OpenAI has acquired Orchestra Bio, a biotech startup.
OpenAI describes Orchestra Bio as “a platform that helps biopharma teams coordinate the complex process of drug development.” The company will bring Orchestra’s team and tech “together with Rosalind, our AI models and tools for life sciences research.”
TL;DR
- OpenAI has acquired the biotech startup Orchestra Bio.
- Orchestra Bio offers a platform to help biopharma teams manage drug development.
- The acquisition will combine Orchestra's resources with OpenAI's Rosalind AI models and life sciences tools.